Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.

The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is rapidly advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV.  Eiger has initiated a rolling NDA submission for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to complete NDA submission and MAA submission in the first quarter of 2020.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa - Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and
Toggle Summary Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago
PALO ALTO, Calif. , April 24, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that an abstract describing prevalence of hepatitis delta virus (HDV) in the U.S. will be presented at Digestive Disease Week (DDW) in Chicago, Illinois , May 6 to 9, 2017 .
Toggle Summary Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif. , Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. , (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC , October 20 to 24, 2017 .
Toggle Summary Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
PALO ALTO, Calif. , March 5, 2018 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV ( LO nafarnib W ith R itonavir in H epatitis D elta V irus) Program will be presented at The International Liver Congress™ meeting in Paris, France ,
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.